February 5, 2026
On February 9, OncoInv will host an exclusive expert meeting at Madrid Health Hub, bringing together leading voices in oncology to discuss the evolving role of multi-cancer detection (MCD) in clinical practice.
MCD is entering a new phase. As the evidence base continues to mature, the central question for oncology systems is no longer whether MCD will become part of routine care, but how and when it can be responsibly integrated. This transition has implications that extend beyond technology alone, raising fundamental questions about clinical decision-making, patient pathways, and the organisation of oncology care.
To explore these challenges, OncoInv is convening a high-level panel of four key opinion leaders in oncology. The discussion will focus on the practical and systemic dimensions of MCD adoption, including clinical validation, ethical considerations, health system readiness, and implementation across existing care models.
Rather than approaching MCD as a standalone innovation, the session is designed as a strategic exchange on how emerging evidence can be translated into sustainable clinical practice. By facilitating an open and informed dialogue among experts, the meeting aims to support more thoughtful decision-making around the future integration of MCD within oncology pathways.
With this initiative, OncoInv reinforces its role as a knowledge partner and convener in multi-cancer detection, contributing to the responsible evolution of oncology care through evidence-based discussion and cross-disciplinary insight.
